Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Watson Acquires Generic Revlimid Rights

December 7, 2010 5:56 am | News | Comments

Watson Pharmaceuticals Inc. said it acquired the U.S. rights to a generic version of Celgene Corp.'s billion-selling cancer drug Revlimid.

TOPICS:

Read Takes Over Troubled Pfizer

December 7, 2010 5:54 am | by Marley Seaman | News | Comments

Pfizer Inc. may be the world's biggest drugmaker, but new CEO Ian Read is taking charge at a trying time for the company, and he will have to deal with a declining share price, repeated failures of potential new products and expirations of patents on key drugs.

TOPICS:

Global Fund Halts Grants for Suspected Fraud

December 7, 2010 5:52 am | by Martin Vogl | News | Comments

The Global Fund to Fight AIDS, Tuberculosis and Malaria said that $4 million meant to fight disease in Mali has been misappropriated, prompting them to halt three grants.

TOPICS:
Advertisement

Aspirin May Reduce Cancer Risk

December 7, 2010 5:51 am | by Maria Cheng | News | Comments

A new report from British scientists suggests that long-term, low-dose aspirin use may modestly reduce the risk of dying of certain cancers, though experts warn the study isn't strong enough to recommend healthy people start taking a pill that can cause bleeding and other problems.

TOPICS:

NovaBay And Galderma Expand Agreement

December 6, 2010 7:39 am | News | Comments

NovaBay Pharmaceuticals, Inc. and Galderma announce the expansion of their multi-year collaboration agreement to include impetigo.

TOPICS:

Questions Raised Over Revlimid Safety

December 6, 2010 7:32 am | News | Comments

A clinical trial investigator said more occurrences of observed secondary malignancies have been found in patients who received a maintenance dose of the myeloma treatment, Revlimid, compared to those who received a placebo.

TOPICS:

Test Better Measures Circulating Tumor Cells

December 6, 2010 7:25 am | News | Comments

Researchers from the A*STAR Institute of Micro-electronics Bioelectronics program in Singapore are developing a cost-effective and more rapid way to help physicians assess the effectiveness of treatments to cancer patients.

TOPICS:

New Test Aids Breast Cancer Patients

December 6, 2010 7:18 am | News | Comments

A team of scientists has collaborated with Pfizer Inc. to develop a test to select which patients with ovarian cancer will benefit from drugs called PARP inhibitors, according to research.

TOPICS:
Advertisement

S*Bio Drug Demonstrates Good Tolerability

December 6, 2010 7:12 am | News | Comments

S*BIO Pte Ltd announced that data from Phase 1/2 studies for its novel JAK2 inhibitor SB1518 indicates clinical efficacy and good tolerability for the treatment of patients with symptomatic myelofibrosis and enlarged spleens.

TOPICS:

FDA Delays Benlysta Decision

December 6, 2010 7:09 am | News | Comments

Human Genome Sciences Inc. and GlaxoSmithKline PLC said that the Food and Drug Administration wants three more months before making a decision on their lupus drug candidate Benlysta, delaying the agency's decision until around March 10.

TOPICS:

Prescription Drugs Heading to the Streets

December 6, 2010 7:06 am | by Carolyn Thompson | News | Comments

Ethel Johnson couldn't get her prescription for pain medication filled fast enough. The 60-year-old Buffalo woman was hurting - but investigators say that wasn't the reason for the rush.

TOPICS:

Kindler Out As Pfizer CEO

December 6, 2010 7:02 am | by Linda A. Johnson | News | Comments

Pfizer Inc. abruptly replaced its CEO and chairman, saying Jeffrey B. Kindler was retiring after 4 1/2 years leading the world's biggest drugmaker to "recharge."

TOPICS:

The Promise of Next-Generation Analytics

December 6, 2010 6:45 am | by Nick Giannasi, PhD, Vice President, Life Sciences Product Strategy; Oracle Corporation, Redwood Shores, Calif. | Articles | Comments

Over the last decade, electronic data capture has fundamentally transformed the way biopharmaceutical companies and regulatory agencies view clinical development activities.

TOPICS:

Mechanistic Ion Channel Screening for Drug Discovery

December 6, 2010 6:38 am | by Glenn Kirsch, PhD, Head, Pharmacological Science; ChanTest Corporation, Cleveland, Ohio | Articles | Comments

The diversity of ion channels, their involvement in a broad spectrum of physiologic mechanisms, and their accessibility on the cell surface make them attractive drug targets.

TOPICS:

Digitally Noted

December 6, 2010 6:13 am | by Catherine Shaffer, Contributing Editor | Articles | Comments

As the life sciences migrate towards a paperless work flow, electronic notebooks are becoming a popular option to manage data, aid in IP searches, and enable collaboration.

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading